KIT and gastrointestinal stromal tumor: In addition, for GIST patients at high risk of relapse, the duration of adjuvant therapy with IM (800 mg/d) (3 years) resulted in a longer progression-free survival (the hazard ratio 0.39; 95% CI; 0.22-0.71, P=0.0013) in patients with KIT exon 9 GISTs (56).